GlassScriptPhysician profile
Vetta Higgs
NPI 1851313993
$1,013.92
in general payments reported to CMS, 2019-2025
24 companies · $27.04 in 2025
The $27.04 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $41.47 · 2021: $40.75 · 2022: $38.03 · 2023: $708 · 2024: $21.82 · 2025: $27.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $121.09 | 2022-2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $97.46 | 2019-2023 | Calquence, Lynparza |
| Amgen INC. | $72.82 | 2021-2023 | Blincyto, Kyprolis, Lumakras |
| Pfizer INC. | $71.09 | 2019-2023 | |
| Seagen INC. | $64.25 | 2023 | Padcev, Tukysa |
| E.R. Squibb & Sons, L.L.C. | $63.92 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $57.39 | 2019-2023 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $52.90 | 2023 | Imbruvica, Darzalex |
| Incyte Corporation | $52.41 | 2023 | Pemazyre, Monjuvi, Jakafi |
| Foundation Medicine, INC. | $43.91 | 2023 | |
| Abbvie INC. | $41.92 | 2022-2024 | |
| Glaxosmithkline, LLC. | $33.69 | 2023 | Zejula, Jemperli |
| Celgene Corporation | $30.02 | 2023 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $27.04 | 2025 | Libtayo |
| Lexicon Pharmaceuticals, INC. | $26.03 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.32 | 2020 | |
| Cti Biopharma Corp. | $20.83 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $20.14 | 2023 | Epkinly, Imbruvica |
| Lilly USA, LLC | $19.66 | 2023 | Jaypirca, Retevmo, Verzenio |
| Astellas Pharma US INC | $17.31 | 2023 | Padcev |
| Exelixis INC. | $15.24 | 2019 | |
| Genzyme Corporation | $13.82 | 2019 | |
| Acrotech Biopharma INC. | $13.42 | 2023 | Beleodaq |
| Novocure INC. | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vetta Higgs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.